Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Maurizio Martini, Alessandra Cassano, Luigi Maria Larocca, Alessandro Inno, Mariantonietta Di Salvatore, Tonia Cenci, Armando Orlandi, Antonia Strippoli, Anna Maria Ferrara, Cinzia Bagala', Carlo Antonio Barone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

62 Citazioni (Scopus)

Abstract

The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought.
Lingua originaleEnglish
pagine (da-a)325-332
Numero di pagine8
RivistaClinical Colorectal Cancer
Volume10
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Colorectal Neoplasms
  • DNA, Neoplasm
  • Drug Resistance, Neoplasm
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoenzyme Techniques
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Metastasis
  • PTEN Phosphohydrolase
  • Polymerase Chain Reaction
  • Prognosis
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins c-met
  • Receptor, Epidermal Growth Factor
  • Receptor, IGF Type 1
  • Retrospective Studies
  • Survival Rate
  • Tumor Markers, Biological
  • ras Proteins

Fingerprint Entra nei temi di ricerca di 'Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?'. Insieme formano una fingerprint unica.

Cita questo